Resverlogix Corp. (TO:RVX) — Market Cap & Net Worth
Market Cap & Net Worth: Resverlogix Corp. (RVX)
Resverlogix Corp. (TO:RVX) has a market capitalization of $20.79 Million (CA$28.73 Million) as of April 29, 2026. Listed on the TO stock exchange, this Canada-based company holds position #24904 globally and #973 in its home market, demonstrating a -4.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Resverlogix Corp.'s stock price CA$0.10 by its total outstanding shares 287344044 (287.34 Million). Explore how resilient are Resverlogix Corp.'s assets to measure the company's liquid asset strength and financial resilience.
Resverlogix Corp. Market Cap History: 2015 to 2026
Resverlogix Corp.'s market capitalization history from 2015 to 2026. Data shows change from $361.68 Million to $20.79 Million (-23.19% CAGR).
Resverlogix Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Resverlogix Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RVX by Market Capitalization
Companies near Resverlogix Corp. in the global market cap rankings as of April 29, 2026.
Key companies related to Resverlogix Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.13 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #350 globally with a market cap of $76.03 Billion USD.
- UCB SA (BR:UCB): Ranked #522 globally with a market cap of $50.68 Billion USD ( €43.35 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.13 Billion | $430.14 |
| #350 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.03 Billion | $731.77 |
| #522 | UCB SA | BR:UCB | $50.68 Billion | €227.70 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Resverlogix Corp. Historical Marketcap From 2015 to 2026
Between 2015 and today, Resverlogix Corp.'s market cap moved from $361.68 Million to $ 20.79 Million, with a yearly change of -23.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$20.79 Million | 0.00% |
| 2025 | CA$20.79 Million | +66.67% |
| 2024 | CA$12.47 Million | -14.29% |
| 2023 | CA$14.55 Million | -50.00% |
| 2022 | CA$29.10 Million | -72.55% |
| 2021 | CA$106.01 Million | -45.74% |
| 2020 | CA$195.39 Million | -23.58% |
| 2019 | CA$255.67 Million | -62.61% |
| 2018 | CA$683.86 Million | +60.49% |
| 2017 | CA$426.11 Million | +20.59% |
| 2016 | CA$353.36 Million | -2.30% |
| 2015 | CA$361.68 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 29th, 2026 the market cap of Resverlogix Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.79 Million USD |
| MoneyControl | $20.79 Million USD |
| MarketWatch | $20.79 Million USD |
| marketcap.company | $20.79 Million USD |
| Reuters | $20.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary sy… Read more